The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab
暂无分享,去创建一个
Eudocia Q Lee | Benjamin M Ellingson | Timothy F Cloughesy | Whitney B Pope | Raymond Y Huang | Patrick Y Wen | Rifaquat Rahman | P. Wen | T. Cloughesy | E. Lee | D. Reardon | E. Galanis | K. Ballman | W. Pope | L. Abrey | B. Ellingson | R. Rahman | David A Reardon | Evanthia Galanis | Karla V Ballman | S Keith Anderson | Lauren E Abrey | Lakshmi Nayak | Sara J Felten | Sara J. Felten | L. Nayak | S. K. Anderson | S. K. Anderson
[1] M. J. van den Bent,et al. Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.
[2] John A Butman,et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Gaylord,et al. AMERICAN ASSOCIATION FOR CANCER RESEARCH. , 1913, California state journal of medicine.
[5] Benjamin M Ellingson,et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. , 2014, Radiology.
[6] Darell D. Bigner,et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.
[7] John Sampson,et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Cloughesy,et al. Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy , 2013, Current Neurology and Neuroscience Reports.
[10] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A Gregory Sorensen,et al. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. , 2013, Neuro-oncology.
[12] Alexander Radbruch,et al. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma , 2014, Neurology.
[13] Rémy Guillevin,et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. , 2012, Neuro-oncology.
[14] Charles Scott,et al. NT-40Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM , 2014 .
[15] Timothy F Cloughesy,et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. , 2008, Neuro-oncology.
[16] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[17] J. Buckner,et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. , 2007, Neuro-oncology.
[18] W. Wick,et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials , 2013, Neuro-oncology.
[19] Tom Mikkelsen,et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.
[20] Alexander Radbruch,et al. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. , 2012, Neuro-oncology.
[21] P. Wen,et al. Response Assessment in Neuro-Oncology , 2011, Current oncology reports.
[22] Timothy F Cloughesy,et al. Clinical trial end points for high-grade glioma: the evolving landscape. , 2011, Neuro-oncology.
[23] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[24] Patrick Y Wen,et al. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Stupp,et al. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. , 2012, European journal of cancer.